Travere Therapeutics CFO Cline Christopher R. exercised Options for 20,000 shares at $17.44 per share and sold 50,508 shares across four transactions on 2026-09-15. The reported prices and resulting holdings give investors the transaction size, sale range and ownership changes tied to the activity.
Key Highlights
- Cline Christopher R. exercised options for 20,000 Travere Therapeutics shares at $17.44 per share.
- Four sales covered 50,508 shares at prices ranging from $62.00 to $65.31 per share.
- Cline’s derivative securities holding fell to 0 after the option exercise, representing 100.0% of his prior holding.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a Pharmaceuticals: Major company. Cline Christopher R. its CHIEF FINANCIAL OFFICER, exercised options covering 20,000 shares at $17.44 per share on 15 September 2026. The exercise left him with 138,016 shares, representing about 14.5% of his resulting share holding. Cline also sold a total of 50,508 Travere Therapeutics shares through four separate transactions on the same date. The sale prices ran from $62.00 to $65.31 per share. Those sales left Cline with 87,508 shares. The sales represented about 36.6% of his prior share holding.
Derivative Securities Holding Reaches Zero
The option exercise covered 20,000 derivative securities. After that transaction, Cline held 0 derivative securities, equal to about 100.0% of his prior derivative securities holding.
FAQs
Q: How many Travere Therapeutics options did Cline Christopher R. exercise?
A: Cline Christopher R. exercised options for 20,000 Travere Therapeutics shares. The exercise price was $17.44 per share on 15 September 2026.
Q: How many Travere Therapeutics shares did Cline sell?
A: Cline sold 50,508 Travere Therapeutics shares across four transactions. The reported sale prices ranged from $62.00 to $65.31 per share.
Q: How many shares did Cline hold after exercising the options?
A: Cline held 138,016 Travere Therapeutics shares after the option exercise. The transaction represented about 14.5% of his resulting share holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.